Anew Labs Raises $290M for AI Drug Discovery
Anew Labs has reportedly raised $290 million at a $1.5 billion valuation after being spun out of ByteDance.
ByteDance's former AI drug-discovery unit has reportedly raised $290 million in its first external financing after becoming an independent company.
What happened
Anew Labs is reported to have raised the round at a $1.5 billion valuation, with HSG, IDG Capital and GL Ventures leading and 5Y Capital co-leading.
The company develops AI systems for biomolecular structure prediction, antibody design and drug discovery.
ByteDance is reported to retain a majority stake after the spinout.
Why it matters
The transaction shows how frontier AI research developed inside large technology companies can become standalone biotech businesses.
Drug discovery is especially capital intensive, so separating the unit can give it access to specialist investors and a financing structure better suited to long research timelines.
The bigger picture
AI-for-science is emerging as one of the most heavily funded areas outside general-purpose models.
The financing has been reported by people familiar with the transaction rather than announced directly by the company, so the terms should be treated as reported rather than company-confirmed. Even so, the scale underscores investor appetite for platforms at the intersection of AI and therapeutics.